EquiCeutica

EquiCeutica is pioneering the use of liposomal nano encapsulation delivery systems with cannabinoids, in the world of human and veterinary medicines, providing unparalleled benefits to the normal dosage forms. We are one of the only companies focusing on regulatory approved CBD products for horses and small animals. Our Pharmaceutical Grade products have been researched and developed utilising the most advanced science available specifically for equine, canine, feline, and human patients. We have worked on formulations and doses used in specific peer reviewed published data. Our research and development has produced an entirely superior pharmaceutical grade CBD product with unparalleled bioavailability efficacy in targeted delivery, inhibiting residue or metabolisation in the liver. EquiCeutica Liposomal CBD is now prescribed by more than 30 of the leading Equine Hospitals/Clinics and Veterinary practices in the UK and the EU. EquiCeutica CBD is used by vets in surgery as part of multi-modal analgesia and also more generally as part of a multi-modal approach to the treatment of chronic pain. It is also used in “end of life” procedures. It is observed to enhance efficacy when used in conjunction with NSAID’s. Vets have observed “successful treatment of emaciated horses that would not eat, anxious horses in the hospital and a stallion”. Prominent competition vets in most international disciplines have observed significantly enhanced recovery times for horses prescribed with EquiCeutica CBD from other conditions including tendon injuries and unresponsive poor performance. Veterinary controlled Field Case Studies have been mostly conducted with equine but consistent positive patient treatment outcomes have been observed with small animals, canine and feline, particularly with older emaciated and immobile dogs suffering with chronic arthritis.